Eradication of Krebs-2 primary ascites via a single-injection regimen of cyclophosphamide and double-stranded DNA

Previously, we reported on the development of a therapeutic regimen allowing eradication of primary murine Krebs-2 ascites transplants. This protocol involved multiple injections of dsDNA preparations administered during the NER and HR phases of repair of interstrand DNA cross-links induced by prior cyclophosphamide treatments. Mice treated under this protocol frequently developed secondary ascites, which indicated that some tumor-inducing cancer stem cells could survive the treatment and caused relapse. Further, we observed that animals receiving multiple dsDNA injections developed pronounced systemic inflammatory response. This prompted us to develop a more straightforward treatment regimen based on the synergistic activity of cyclophosphamide and dsDNA preparations, which would allow complete eradication of established primary Krebs-2 ascites and also be less toxic for the treated animals. This protocol relies on a precisely timed single injection of dsDNA during the NER/HR transition period of each repair cycle. Under this protocol, 8-day remission of Krebs-2 engrafted mice was achieved, which was similar to the results of the multiple-injection treatment schedule. We observed an increase in the average life span of Krebs-2- transplanted mice on a single-injection regimen, which was consistent with reduced toxicity of such treatment.

1. Alyamkina E.A., Dolgova E.V., Likhacheva A.S., Rogachev V.A., Sebeleva T.E., Nikolin V.P., Popova N.A., Orishchenko K.E., Strunkin D.N., Chernykh E.R., Zagrebelniy S.N., Bogachev S.S., Shurdov M.A. Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice. Genet Vaccines Ther. 2009;7(1):12. DOI 10.1186/1479-0556-7-12.

2. Alyamkina E.A., Dolgova E.V., Likhacheva A.S., Rogachev V.A., Sebeleva T.E., Nikolin V.P., Popova N.A., Kiseleva E.V., Orishchenko K.E., Sakhno L.V., Gel’fgat E.L., Ostanin A.A., Chernykh E.R., Zagrebelniy S.N., Bogachev S.S., Shurdov M.A. Exogenous allogenic fragmented double-stranded DNA is internalized into human dendritic cells and enhances their allostimulatory activity. Cell. Immunol. 2010a;262(2):120-126.

3. Alyamkina E.A., Leplina O.Y., Sakhno L.V., Chernykh E.R., Ostanin A.A., Efremov Y.R., Shilov A.G., Proskurina A.S., Orishchenko K.E., Dolgova E.V., Rogachev V.A., Nikolin V.P., Popova N.A., Zagrebelniy S.N., Bogachev S.S., Shurdov M.A. Effect of doublestranded DNA on maturation of dendritic cells in vitro. Cell. Immunol. 2010b;266(1):46-51.

4. Alyamkina E.A., Nikolin V.P., Popova N.A., Dolgova E.V., Proskurina A.S., Orishchenko K.E., Efremov Y.R., Chernykh E.R., Ostanin A.A., Sidorov S.V., Ponomarenko D.M., Zagrebelniy S.N., Bogachev S.S., Shurdov M.A. A strategy of tumor treatment in mice with doxorubicin- cyclophosphamide combination based on dendritic cell activation by human double- stranded DNA preparation. Genet. Vaccines Ther. 2010c;8:7. DOI 10.1186/1479-0556-8-7.

5. Alyamkina E.A., Nikolin V.P., Popova N.A., Minkevich A.M., Kozel A.V., Dolgova E.V., Efremov Y.R., Bayborodin S.I., Andrushkevich O.M., Taranov O.S., Omigov V.V., Rogachev V.A., Proskurina A.S., Vereschagin E.I., Kiseleva E.V., Zhukova M.V., Ostanin A.A., Chernykh E.R., Bogachev S.S., Shurdov M.A. Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts. Cancer Cell Int. 2015;15:32. DOI 10.1186/s12935-015-0180-6.

6. Dolgova E.V., Alyamkina E.A., Efremov Y.R., Nikolin V.P., Popova N.A., Tyrinova T.V., Kozel A.V., Minkevich A.M., Andrushkevich O.M., Zavyalov E.L., Romaschenko A.V., Bayborodin S.I., Taranov O.S., Omigov V.V., Shevela E.Y., Stupak V.V., Mishinov S.V., Rogachev V.A., Proskurina A.S., Mayorov V.I., Shurdov M.A., Ostanin A.A., Chernykh E.R., Bogachev S.S. Identification of cancer stem cells and a strategy for their elimination. Cancer Biol. Ther. 2014;15(10):1378- 1394. DOI 10.4161/cbt.29854.

7. Dolgova E.V., Rogachev V.A, Nikolin V.P., Popova N.A., Likhacheva A.S., Alyamkina E.A., Sebeleva T.E., Chernykh Е.R., Gelfgat E.L., Bogachev S.S., Shurdov M.A. The leukocyte- stimulating action of protamine-protected exogenous DNA in -myelosuppression induced in mice by cyclophosphane. Voprosy onkologii = Problems in Oncology. 2009;55(6):761-764. (in Russian)

8. Peshkova I.V., Bogachev S.S., Drobyazgin E.A., Chikinev Y.V., Mitrofanov I.M., Piontkovskaya K.A., Vereschagin E.I. Effect of glutamine on the nucleic acids exchange during the perioperative period in reconstructive esophagus surgery. J. Nutr. Health Food Eng. 2015;2(4):00058. DOI 10.15406/jnhfe.2015.02.00058.

9. Potter Е.А., Dolgova Е.V., Minkevich А.М., Efremov Y.R., Taranov О.S., Omigov V.V., Nikolin V.P., Popova N.A., Proskurina А.S., Vereschagin Е.I., Kozel А.V., Rogachev V.А., Petrov D.B., Ostanin А.А., Chernykh Е.R., Kolchanov N.А., Bogachev S.S. Therapeutic effects of cyclophosphamide, dsDNA preparations and their combinations against Krebs-2 ascites cancer cells and various cancer transplants. Vavilovskii Zhurnal Genetiki i Selektsii = Vavilov Journal of Genetics and Breeding. 2016a;20(1):96-107. DOI 10.18699/VJ15.116. (in Russian)

10. Potter Е.А., Dolgova Е.V., Minkevich А.М., Nikolin V.P., Popova N.A., Efremov Y.R., Baiborodin S.I., Rogachev V.А., Proskurina А.S., Kozel А.V., Taranov О.S., Omigov V.V., Vereschagin Е.I., Petrov D.B., Ostanin А.А., Chernykh Е.R., Kolchanov N.А., Bogachev S.S. Analysis of different therapeutic schemes combining cyclophosphamide and double-stranded DNA preparations for eradication of Krebs-2 primary ascites in mice. Vavilovskii Zhurnal Genetiki i Selektsii = Vavilov Journal of Genetics and Breeding. 2016b;20(1):108-124. DOI 10.18699/VJ15.117. (in Russian)

11. Scharovsky O.G., Mainetti L.E., Rozados V.R. Metronomic chemotherapy: changing the paradigm that more is better. Curr. Oncol. 2009; 16(2):7-15.